VestGen Advisors’s Capricor Therapeutics CAPR Stock Holding History

VestGen Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$191K	Buy	+20,164	New	+$223K	0.01%	1004

Other funds holding CAPR

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Black Diamond Financial Towson, Maryland $1.18B AUM 15.24% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

VestGen Advisors's CAPR Position: Q3 2026 in Review

VestGen Advisors opened a new position in Capricor Therapeutics (CAPR) in Q3 2026: 20,164 shares worth $191K. The stake represents 0.01% of the portfolio and ranks #1004 among its holdings.

25 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

VestGen Advisors held 20,164 shares of Capricor Therapeutics worth $191K as of Q3 2026.
Capricor Therapeutics was a new VestGen Advisors position in Q3 2026.
Capricor Therapeutics made up 0.01% of VestGen Advisors's portfolio in Q3 2026, its #1004 holding.
25 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on VestGen Advisors's 13F filing for Q3 2026, filed 27 Oct 2026.